Ausdal Financial Partners Inc. Has $833,000 Position in Pfizer Inc. (PFE)
Ausdal Financial Partners Inc. increased its holdings in Pfizer Inc. (NYSE:PFE) by 7.0% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 23,343 shares of the biopharmaceutical company’s stock after purchasing an additional 1,517 shares during the quarter. Ausdal Financial Partners Inc.’s holdings in Pfizer were worth $833,000 at the end of the most recent reporting period.
Several other institutional investors have also modified their holdings of the stock. Janus Henderson Group PLC boosted its position in Pfizer by 243.5% during the second quarter. Janus Henderson Group PLC now owns 13,175,187 shares of the biopharmaceutical company’s stock valued at $442,574,000 after acquiring an additional 9,339,749 shares during the last quarter. Vanguard Group Inc. boosted its position in Pfizer by 2.3% during the second quarter. Vanguard Group Inc. now owns 418,639,111 shares of the biopharmaceutical company’s stock valued at $14,062,088,000 after acquiring an additional 9,239,499 shares during the last quarter. Renaissance Technologies LLC acquired a new position in shares of Pfizer during the second quarter valued at about $268,389,000. Canada Pension Plan Investment Board raised its holdings in shares of Pfizer by 249.6% during the second quarter. Canada Pension Plan Investment Board now owns 10,713,626 shares of the biopharmaceutical company’s stock valued at $359,871,000 after purchasing an additional 7,649,416 shares during the period. Finally, Longview Partners Guernsey LTD raised its holdings in shares of Pfizer by 32.0% during the third quarter. Longview Partners Guernsey LTD now owns 24,369,672 shares of the biopharmaceutical company’s stock valued at $869,997,000 after purchasing an additional 5,901,100 shares during the period. 69.74% of the stock is currently owned by institutional investors.
Shares of Pfizer Inc. (NYSE PFE) opened at $36.56 on Friday. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.43 and a quick ratio of 1.15. Pfizer Inc. has a fifty-two week low of $30.90 and a fifty-two week high of $37.35. The firm has a market cap of $217,920.00, a PE ratio of 22.43, a P/E/G ratio of 2.46 and a beta of 1.01.
Pfizer announced that its board has authorized a share buyback program on Monday, December 18th that allows the company to repurchase $10.00 billion in outstanding shares. This repurchase authorization allows the biopharmaceutical company to buy shares of its stock through open market purchases. Stock repurchase programs are generally a sign that the company’s board of directors believes its stock is undervalued.
The firm also recently announced a quarterly dividend, which will be paid on Thursday, March 1st. Investors of record on Friday, February 2nd will be issued a $0.34 dividend. This represents a $1.36 dividend on an annualized basis and a dividend yield of 3.72%. The ex-dividend date is Thursday, February 1st. This is a positive change from Pfizer’s previous quarterly dividend of $0.32. Pfizer’s dividend payout ratio is currently 78.53%.
In related news, EVP Rady A. Johnson sold 8,000 shares of the company’s stock in a transaction dated Friday, December 15th. The shares were sold at an average price of $37.07, for a total value of $296,560.00. Following the sale, the executive vice president now owns 46,963 shares in the company, valued at approximately $1,740,918.41. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Alexander R. Mackenzie sold 14,700 shares of the company’s stock in a transaction dated Wednesday, November 1st. The stock was sold at an average price of $35.30, for a total transaction of $518,910.00. Following the completion of the sale, the insider now owns 117,432 shares in the company, valued at approximately $4,145,349.60. The disclosure for this sale can be found here. Insiders sold a total of 29,450 shares of company stock worth $1,065,220 in the last 90 days. 0.06% of the stock is currently owned by company insiders.
Several equities analysts have recently weighed in on the stock. BMO Capital Markets set a $39.00 price objective on shares of Pfizer and gave the company a “buy” rating in a report on Monday. Vetr upgraded shares of Pfizer from a “hold” rating to a “buy” rating and set a $37.98 price objective on the stock in a report on Monday. Morgan Stanley set a $41.00 price objective on shares of Pfizer and gave the company a “buy” rating in a report on Friday, January 5th. Jefferies Group set a $38.00 price objective on shares of Pfizer and gave the company a “neutral” rating in a report on Monday, October 16th. Finally, Nord/LB reiterated a “neutral” rating on shares of Pfizer in a report on Tuesday, January 2nd. Two equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and thirteen have issued a buy rating to the stock. The company has a consensus rating of “Buy” and an average target price of $38.83.
ILLEGAL ACTIVITY WARNING: This news story was first reported by Watch List News and is the sole property of of Watch List News. If you are accessing this news story on another domain, it was stolen and reposted in violation of U.S. and international copyright and trademark law. The legal version of this news story can be accessed at https://www.watchlistnews.com/ausdal-financial-partners-inc-has-833000-position-in-pfizer-inc-pfe/1803776.html.
Pfizer Company Profile
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.